Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on August 13, 2019. The report addresses corporate governance changes effective as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Board Resignation: Shlomo Yanai resigned from the Company's Board of Directors for personal reasons, effective August 13, 2019.
- Board Appointment: The Board appointed Zeev Bronfeld, a current independent director, to serve as the new Chairman of the Board.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the disclosed leadership transition.
Key Facts for Investor Verification
- Confirm the effective date of Shlomo Yanai's resignation (August 13, 2019).
- Verify the appointment of Zeev Bronfeld as Chairman of the Board.
- Review the press release filed as Exhibit 99.1 for additional context on the resignation.